SCOPE Analytic Treatment Interruption Protocol
Recruiting
Analytic Treatment Interruption in HIV Infection
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Willing and able to provide written informed consent * Age \>= 18 * Documented HIV infection * Antiretroviral therapy for at least 12 months * Screening plasma HIV RNA levels below level of detection (\< 40-75 copies/mL), and all available determinations in past 12 months also below level of detection (blips allowed) * Screening CD4+ T-cell count \>350 cells/uL * If of childbearing potential, willing to use two methods of contraception * Willing to receive counseling regarding HIV transmission risk mitigation Exclusion Criteria: * Pregnant or plans to become pregnant during the course of the study * Active hepatitis B, defined as (1) positive sAg or (2) positive cAb with negative sAb and positive HBV DNA * Active hepatitis C, defined as positive Hep C Ab with positive HCV RNA * Use of a non-nucleoside reverse transcriptase inhibitor and unable to switch regimen * Significant cardiovascular or cerebrovascular disease * Recent or prior (within past 5 years) malignancy * Severe kidney disease (CrCl \< 50 mL/min via Cockroft-Gault method) * Severe hepatic impairment (Child-Pugh Class C) or unstable liver disease * Concurrent treatment with immunomodulatory drugs * Unable or unwilling to use barrier protection or pre-exposure prophylaxis (PrEP) to prevent HIV transmission with sexual partners not known to be HIV-infected
About the study
The goal of this study is to understand the interaction between HIV and the host at the earliest stages when HIV medications are paused. Volunteers with HIV will interrupt antiretroviral therapy (ART) and then have intensive studies preformed two to three times per week. Most will resume therapy within three weeks, even if the virus does not rebound during this time.
What is being tested
- Treatment Interruption Arm (other)
Sponsor: University of California, San Francisco · Participants: 40 · Started: Oct 15, 2020
Contact the study team
- Steven Deeks, MD · Phone: 415-476-4082
- Michael Peluso, MD · Phone: 415-476-9363
Official record on ClinicalTrials.gov — NCT04359186
Locations in the U.S.
| California | University of California San Francisco, San Francisco |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.